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                     Men Medically Assisted to Reproduce:
AID, IVF, and ICSI, an Assessment
of the Revolution in the Medical Treatment
of Male Factor Infertility*
Élise de LA ROCHEBROCHARD**
The introduction of in vitro fertilization (IVF) at the begin-
ning of the 1980s made possible the treatment of female factor in-
fertility. At that time the main technique used for male problems
was artificial insemination by donor (AID), though in France this
has always met with considerable resistance both from men and
from women. Élise de LA ROCHEBROCHARD shows that a turning
point occurred in the 1990s with the emergence and rapid exten-
sion of ICSI (intracytoplasmic sperm injection), a new technique
for the treatment of male factor infertility. ICSI has led to a
decline in the use of AID and has stabilized the use of “conven-
tional” IVF. With ICSI, however, male infertility continues to be
treated in the bodies of women. The rapid development of this new
technique, not all of whose consequences have yet been fully eva-
luated, raises important issues which are addressed in this article.
With the wide diffusion of medicalized contraception (Leridon et al.,
1987; Leridon et al., 2002), women could have the impression that they are
living out the famous feminist slogan of the 1970s “A child if I want, when
I want”. Yet once the decision to have a child has been taken and contracep-
tion has been stopped, the couple’s control over events ceases and a child
may not happen. Of 100 young couples who embark on this adventure, a
pregnancy leading to a live birth is started by 20-25 in the first month,
while 65-70 conceive during the first six months and 80-85 during the first
year (Spira, 1986; de Mouzon et al., 1988; Leridon, 1992). At the end of
* Translator’s note: Demographers distinguish reproductive capacity from reproductive per-
formance, and in demographic writing the term “infecundity” corresponds to involuntary infertility.
English-language epidemiologists do not usually make this distinction, and for this reason the pre-
sent article, though published in a journal of demography, retains the terms “male factor infertility”
and “female factor infertility”. They denote what demographers refer to as “infecundity”.
Translated by Accenta Ltd.
** Institut National d’Études Démographiques et Institut National de la Santé et de la
Recherche Médicale, Paris.Population-E 2003, 58(4-5), 487-522
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                               this year of waiting, it would seem legitimate for the 15-20 couples who
have not conceived to consult a doctor to discuss this involuntary infertility.
In reality, couples can begin to worry well before a year is up. The
“Family Situations and Employment” survey conducted by INED and
INSEE enables us to measure this worry with two indicators(1). First,
women were asked about the existence of perceived difficulties through the
question: “Has it ever taken you longer than you wanted to get pregnant
before finally succeeding?”. Among the women who mentioned such diffi-
culties in becoming pregnant, 30% reported having conceived before the
end of the first year of trying (while 19% had conceived at the end of one
year and 51% after more than one year). The second indicator deals with
the time before consultation, a question that was put to women but also to
men. Among those who have seen a doctor about infertility (women or/and
their partner), 41% did so when they and their partner had been trying to
conceive for less than a year (while 31% reported having consulted by the
end of one year and 28% after this first anniversary)(2). These two indica-
tors support the hypothesis of a growing “impatience” in couples, a hy-
pothesis derived from a comparative analysis of fertility surveys between
1978 and 1988 published under the title “Sterility and subfecundity: from
silence to impatience?” (Leridon, 1992).
A few decades ago, infertility would probably have been categorized
among “women’s problems”(3). Today, couples also have to consider the
possibility that their problems could be of male origin. This issue of the
origin of infecundity was explored in a survey of couples going to the doc-
tor about infertility between July 1988 and June 1999 in the French
départements of Indre-et-Loire, Loire-Atlantique and Haute-Vienne
(Thonneau et al., 1991). Medical tests conducted on these couples re-
vealed a sperm abnormality in three out of five cases (Table 1). These were
mainly anomalies in the so-called conventional characteristics of sperm
(number, motility, morphology). Nevertheless, other criteria for evaluating
sperm quality have been proposed and it has been suggested that a propor-
tion of idiopathic (i.e. unexplained) infertility could well be due to the
male partner, with the man exhibiting a sperm abnormality not measured
by the conventional criteria (Irvine, 1998)(4).
(1) Unpublished data. This survey was carried out in 1994 on a representative sample of
men (n=1,966) and women (n=3,007) aged from 18 to 49.
(2) More women than men reported having consulted a doctor before the end of the first
year (44% of women against 37% of men, p=0.3%).
(3) The anthropologist Françoise Héritier-Augé observes that the woman is considered res-
ponsible for sterility in nearly every human society (Héritier-Augé, 1985, p. 12).
(4) D. Stewart Irvine (1998) discusses the difficulties of diagnosing male factor infertility.
Generally, male factor infertility is diagnosed from the so-called conventional characteristics of
sperm (number, motility, morphology) which are compared with recognized criteria of normality
(Crosignani et al., 1994; van den Eede, 1995). However, this procedure has limits: (i) variability
in spermatic characteristics exists between sperm samples from the same man; (ii) evaluation of
spermatic characteristics suffers a degree of subjectivity which is reflected in a variability of re-
sults between analysis laboratories; (iii) criteria for normal sperm have been published by WHO
but their pertinence for diagnosing male factor infertility is contested.
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                    TABLE 1.– ORIGIN OF INFERTILITY IN COUPLES
Origin of infertility Distribution
Male related factors only 20% } 58% male infertility of which: {   9% azoospermiaCombination of male/female factors 38% 49% oligo – terato – asthenospermia
Female related factors only 34%
Idiopathic (unexplained) 8%
Source: Survey carried out on 1,686 couples who consulted a doctor for infertility between July 1988 and June 1989 in Indre-et-Loire, Loire-Atlantique and Haute-
Vienne, France (Thonneau et al., 1991).489
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       Whatever the case, in the area of infertility, the medical search for a
“guilty party” seems inadequate: in two cases out of five, medical exami-
nation reveals a cause with both female and male origins (Table 1). This
result has led the authors of the French survey to conclude that infertility
is first and foremost a “couple’s problem”.
The proportion of male factor infertility could increase in the years
to come. Research in developed countries has revealed changes in conven-
tional spermatic characteristics over the last fifty years (Carlsen et al.,
1992; de Mouzon et al., 1996). These changes, both quantitative and quali-
tative, point to the possibility of an increase in male factor infertility in
the younger generations.
After describing the data collection systems on assisted conception
in France and the rest of the world, this article analyses the medical treat-
ment for male factor infertility in the different techniques of medically as-
sisted reproduction. On the one hand, in vitro fertilization has very low
success rates in cases of severe male factor infertility (this technique hav-
ing originally been developed to treat female factor infertility). On the
other hand, success rates with artificial insemination by donor are satisfac-
tory but the couple has to accept the use of donor sperm. The choice
between these two techniques thus made the medical management of male
factor infertility problematical until the development of intracytoplasmic
sperm injection ten years ago. We shall see that although this new tech-
nique has become widely employed, it nonetheless raises a number of
questions.
I. Data collection systems
on assisted reproduction
The techniques of in vitro fertilization (IVF) were developed as a
response to infertility problems. IVF involves retrieving oocytes (by
follicular aspiration) and collecting spermatozoa — generally from part-
ners, sometimes from donors — to carry out the fertilization in the labora-
tory. Once the oocyte is fertilized and has developed into an embryo, it is
r ep l aced  in  t he  woman’s  u t e rus  o r  fa l l op i an  t ubes .  Th i s  i s  how
Louise Brown, known as “the first test tube baby”, was born in the suburbs
of Manchester (England) on 25 July 1978 (Steptoe and Edwards, 1978).
France had to wait until 24 February 1982 for the birth of its “first test
tube baby”, named Amandine, at the Antoine-Béclère Hospital in Clamart
(Testart and Frydman, 1982).
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                1. The diffusion of IVF in France …
The years following the birth of Amandine saw a rapid increase
in the number of IVF treatments carried out in France,  and around
5,000 “test tube” babies were born annually in the period 1990-1992.
The introduction of this new medical technique brought with it a
number of questions. In particular it was felt necessary to evaluate the po-
tential risks to the child and to the woman (Breart and de Mouzon, 1995).
Hence it was for reasons both of public health and of research that a pros-
pective survey known as FIVNAT, the National IVF registry(5), was set up
in France in 1986 (de Mouzon et al., 1993; FIVNAT, 1993). This survey is
based on an exhaustive data collection from the IVF centres that volun-
teered to take part. Two forms are collected. The “attempt” form describes
the infertility assessment of the couple and the progress of the IVF attempt
(follicular aspiration, transfer of embryo(s), and whether or not a preg-
nancy is obtained). The “pregnancy” form describes the medical progress
of the pregnancy, its outcome and the health status of the child(ren) at
birth. Between 1986 and 2000, FIVNAT processed over 340,000 “attempt”
forms and more than 29,000 “pregnancy” forms.
In parallel to FIVNAT, a national data collection system was set up
to obtain a comprehensive estimate of the number of IVF procedures car-
ried out in France. This system is based on the annual activity reports from
the centres, which were initially collected in the context of GEFF (French
In Vitro Fertilization Study Group)(6) and are now collected by compul-
sory reporting to the Ministry of Health(7). The activity reports must also
indicate the outcome of the pregnancies resulting from IVF (and therefore
the number of children), but this system suffers from a problem of infor-
mation feedback between the maternity hospitals where the children are
born and the IVF centres. In particular, it is thought that the number of
births declared in the activity reports is underestimated.
By combining these two sources (FIVNAT survey and annual activity
reports of the IVF centres) it is possible to estimate IVF activity in France.
(5) FIVNAT is an association governed by an executive committee elected every two years
at the FFER’s (French Federation for the Study of Reproduction) conference. Under the supervi-
sion of an epidemiologist, Dr Jacques de Mouzon (INSERM), the data coding, verification,
processing, and analysis are undertaken at the Kremlin-Bicêtre Hospital (94), by members of the
joint INED-INSERM research unit. A report and more specific analyses are published annually.
An introduction to FIVNAT and the results generated by this survey are available at the following
address: http://perso.wanadoo.fr/fivnat.fr/.
(6) GEFF’s reports were published annually in issues 7-8 of Contraception, Fertilité,
Sexualité between 1987 and 1992.
(7) Law no. 94-654, 29 July 1994 regarding the donation and use of elements and products
of the human body for medically assisted reproduction and prenatal diagnosis. Article L. 184-2:
“Every establishment or laboratory authorized to perform medically assisted procreation or pre-
natal diagnosis and any multidisciplinary centre performing prenatal diagnosis is required to
present an annual activity report to the Minister of Health, according to the terms set down by the
decree of the said Minister. The aforementioned establishments are also required to establish and
maintain records, under conditions set out by the decree of the Council of State, relative to the
gametes and embryos they are holding.”
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               The activity reports provide an exhaustive account of the number of as-
sisted fertilization cycles performed in France, and the FIVNAT survey is
used to measure the success rates (pregnancies, deliveries, children) under
the assumption that the centres contributing to FIVNAT have success rates
identical to those of centres as a whole. This approximation may result in
a slight overestimation of the number of children born by IVF in France,
but it can be judged satisfactory in view of the high coverage achieved by
the FIVNAT survey, which recorded 92% of the oocyte retrievals per-
formed in France in 1995-1999 (84% in 1986-1999)(8).
Between 1982 and 1999, more than 66,500 deliveries were obtained
after  IVF treatment,  result ing in the bir th of  over 85,000 children
(Table 2)(9). These figures reflect the high rate of multiple births, with
127-130 children for 100 deliveries (FIVNAT, 1995). The development of
IVF is one of the causes of the increase in multiple births. While one in
100 deliveries resulted in twins between 1901 and 1970, by the 1990s this
was the case for one in 75 deliveries (Daguet, 2002). The other factors ex-
plaining the increase in multiple births are the development of hormone
stimulation treatment, better medical management of multiple pregnan-
cies, and, to a lesser extent, the increase in births to women aged 35-39.
These high rates of multiple pregnancies have significant consequences for
the children as they are associated with a high risk of prematurity and
hence of morbidity (Epelboin and Blondeau, 1989; Laborie, 1994a;
Dehan, 1998; Olivennes, 2001; Papiernik and de Mouzon, 2002).
2. … and in the rest of the world
What is the situation in the rest of the world? For the past twenty five
years, five worldwide reports on IVF activities have been published by the
International Working Group on Assisted Reproduction (IWGROAR) and
then by the International Committee on Monitoring of Assisted Reproduc-
tive Techniques (ICMART). They report activity in several dozen coun-
tries for 1989, 1991, 1993, 1995 and 1998(10). The last worldwide report
was partly based on information supplied by three existing regional regis-
ters: the European register, the register for Australia and New Zealand,
and the Latin American register. In all, about forty countries participated
in the 1998 report and 59% of them reported their activity in full.
IVF treatment is performed chiefly in developed countries. However,
the World Health Organization recently received a request for advice on the
(8) FIVNAT’s coverage rate was 61% in 1986, the first year of data collection and reached
94% as of 1993.
(9) The retrievals reported in Table 2 are those performed during conventional IVF but also
ICSI (see below).
(10) These reports were published in the proceedings of the conferences at which they were pre-
sented: the world conferences on “In Vitro Fertilization and Assisted Reproductive Techniques” for the
reports of 1989 (Paris, France, June 1991), 1991 (Kyoto, Japan, September 1993) and 1997
(Vancouver, Canada, May 1997) ; the world conferences on “Fertility and Sterility” for the reports of
1993 (Montpellier, France, September 1995) and 1998 (Melbourne, Australia, November 2001).
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                                                TABLE 2.– MEDICALLY ASSISTED FERTILIZATION IN FRANCE, 1982-1999 (ESTIMATES)
Year Authorized centres
Cycles(a) Clinical
pregnancies(d) Deliveries
(d) Children(d)
Retrievals(b) FER(c)
1982-1985(e) – 12,000 – 1,400 900 1,000
1986 55 11,779 – 1,767 1,413 1,838
1987 92 18,617 1,409 3,252 2,370 3,065
1988 121 23,143 1,840 4,251 3,124 4,040
1989 115 25,648 2,137 4,841 3,489 4,511
1990 130 27,963 2,682 5,578 4,055 5,239
1991 109 27,498 2,827 5,174 4,007 5,178
1992 102 26,063 2,728 5,172 3,792 4,893
1993 95 26,140 2,784 5,660 4,082 5,269
1994 97 28,920 3,478 6,069 4,639 5,989
1995 101 33,000 4,194 7,007 5,173 6,661
1996 88 35,325 5,173 8,425 6,158 7,890
1997 94 38,752 6,686 9,345 6,925 8,797
1998 96 39,800 7,000 9,617 8,187 10,331
1999 96 41,000 7,500 10,808 8,462 10,675
Total(f) 415,648 50,438 88,366 66,776 85,376
(a)
 The number of cycles (oocyte retrievals and FER) come from the centres’ activity reports. These reports were initially prepared in the context of the GEFF survey
(French In Vitro Fertilization Study Group) and are now collected through compulsory statements to the Ministry of Health. The first reports were published in the journal
Contraception, Fertilité, Sexualité. The unpublished data were supplied by Dr Jacques de Mouzon (INSERM), who is responsible for preparing the annual reports.
(b)
 Retrievals performed in the context of any medically assisted fertilization technique, the two most important being conventional IVF and ICSI (intracytoplasmic sperm
injection).
(c)
 FER=Frozen Embryo Replacement. During an IVF attempt, some of the embryos may be frozen for transfer in a future attempt. Freezing of embryos is offered parti-
cularly when the number of embryos obtained exceeds the number transferred.
(d)
 The number of pregnancies, deliveries, and children indicated in the centres’ reports are underestimated since a proportion of the pregnancies were lost to observation
before coming to term. From 1986, the numbers presented here are an estimate based on the hypothesis of a success rate in France identical to that observed in the
FIVNAT survey. For example, in 1990, a pregnancy rate per retrieval of 18.7% was observed in FIVNAT, and a pregnancy rate per FER of 13.0%, which gives an estimate
of the number of pregnancies in France as: 27,963 retrievals×0.187+2,682 FER×0.130=5,578 pregnancies.
(e)
 For the 1982-1985 period, it is an aggregated estimate for the 4 years.
(f)
 For the 1982-1999, period, the 415,648 retrievals performed resulted in 81,445 pregnancies, 62,022 deliveries, and 79,815 children. The 50,438 FER resulted in 6,921
pregnancies, 4,754 deliveries, and 5,561 children.
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     setting up and use of assisted reproductive techniques (ART) from develop-
ing countries where ART is provided mainly in private clinics (Vayena et
al., 2002). Some developed countries have experienced a very rapid growth
of IVF in recent years. In Japan, for example, between 1995 and 1998, the
number of IVF centres increased exponentially, from 96 to 425. As a result
of this large increase, Japan carried out more than 53,000 retrievals in
1998, placing it between the United States, which carries out the most
(over 60,000), and the three main European countries (France, Germany,
United Kingdom), which each carried out 40,000 retrievals in 1998. Europe
is by far the continent where recourse to assisted fertilization is greatest.
3. Use of IVF in Europe
In Europe, the European Society for Human Reproduction and Em-
bryology (ESHRE) proposed in 1999 a programme to centralize the data
on IVF from the information collected in individual countries. This pro-
gramme has already resulted in the publication of two reports, for 1997
and 1998 (Nygren and Andersen, 2001a and 2001b). In 1998, eighteen
countries took part in the programme (Table 3). However, only nine coun-
tries supplied exhaustive data, for although northern Europe has compre-
hensive national registers, this is not the case for southern and eastern
Europe, while western Europe is split between these two groupings. In ad-
dition, the authors of the report noted a variability in the quality of the re-
ported data (widely varying coverage rates, different rates of pregnancies
lost to observation with countries such as Switzerland where information
on deliveries and children remains very fragmented, differences in defini-
tions between countries, etc.). Faced with these difficulties, the European
Consortium is currently working to improve the data collection system; at
the time of writing, a comparative analysis of the progression of IVF in
Europe remains a difficult exercise.
It is possible, however, to estimate a range of values for the number
of cycles performed in the countries for which comprehensive data are
lacking (Table 3). For these countries, the number of cycles recorded
forms the lower limit of the number of cycles performed; moreover, we
make the assumption that the centres not included in the report have levels
of activity identical to those of the centres that were. This probably leads
to overestimating IVF activity (in particular for those countries with a low
coverage rate, such as Spain) and this estimate is taken to be the upper
limit of the number of cycles performed. Dividing the number of cycles
thus estimated by the number of women aged 15-49 in each country, gives
an indicator for the rate of recourse to IVF. This rate varies between 1 (in
Russia) and 66 (in Denmark) per 10,000 women of childbearing age. In
France, the rate of IVF use is 32 cycles per 10,000 women of childbearing
age, which is close to that observed in the Netherlands, Finland, and
Norway. In Germany, Switzerland, and the United Kingdom the rate of
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         IVF use is lower (in the region of 23 to 28 per 10,000), while in Belgium,
Denmark, Sweden, and Iceland it is higher (over 40 per 10,000).
By adopting a similar approach, it is possible to estimate a range of
values for the children born after assisted fertilization as a percentage of
all the children born in each country (Table 3). In 1999, 1.4% of children
were born after assisted fertilization in France. The percentage of children
born through IVF is strongly associated with the number of cycles per-
formed per 10,000 women (Figure 1a): this percentage increases by 1%
when the number of cycles performed per 10,000 women of childbearing
age increases by 20 units.
The variations in recourse to IVF between European countries raises
the question of the reasons for such differences. A first possibility is to at-
tempt to explain “simply” the variations in IVF use on the basis of each
country’s characteristics. In this perspective, it could be thought that devel-
opment of the practice is correlated with the country’s fertility dynamics,
whereby a population wishing to have children would perhaps be more
likely to use IVF. Figure 1b shows the variations in IVF use in relation to
the total fertility rate (TFR): the association appears tenuous. The use of
IVF could also reflect the sterility problems experienced in a population,
but no indicator exists for measuring the level of sterility directly(11). In
historical cohorts, the rate of permanent sterility was no doubt linked to the
level of involuntary infertility. This rate was relatively stable up to the co-
horts born during the 1960s, but increased greatly in subsequent cohorts, as
it came to reflect not only involuntary infertility but also voluntary inferti-
lity (Sardon, 2002). Table 3 indicates the rate of permanent sterility for the
1955 cohort, which we assume to be strongly associated with the level of
involuntary infertility. Once again, no clear association is seen between this
rate and the frequency of IVF use (Figure 1c). Other explanations can still
be imagined, in particular involving economic considerations, such as the
level of health care expenditure (Table 3). But this explanation appears to
be no more pertinent than the previous ones (Figure 1d). These first ele-
ments do not therefore add to our understanding of the pattern of IVF use
in Europe. For further progress in this area, it might be useful to study the
conditions of infertility treatment in European countries, for example, by
examining the economic cost to couples of IVF (according to whether or
not it is paid for by social security systems which vary markedly between
countries(12)), the availability of in vitro fertilization (the level of expertise
(11) For demographers the notion of sterility is the opposite of fecundity, signifying the
ability to conceive and have a full-term pregnancy (Leridon, 1981). To measure the level of steri-
lity in a population, demographers have suggested using an indirect indicator: the level of invo-
luntary infertility, i.e. the percentage of married women remaining involuntarily childless.
(12) For example, the authors of an article analysing the economic implications of medi-
cally assisted reproductive techniques (Garceau et al., 2002) point out that the cost of IVF treat-
ment is fully reimbursed in France and partially so in Belgium, Denmark, and Norway. The
United Kingdom is characterized by a large regional variation in public funding; on a national
level only one in four IVF treatments are publicly funded.
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                        TABLE 3.– MEDICALLY ASSISTED FERTILIZATION IN 18 EUROPEAN COUNTRIES, 1998 (ESTIMATES)
Country % of centres 
recorded
Number
of cycles(a)
Number of cycles 
per 10,000 women
aged 15-49
% of children 
born by assisted 
fertilization(b)
Total fertility rate 
(children
per woman)
Permanent steri-
lity rate of the 
1955 cohort
Health expendi-
ture per head
in 1998 (PPS)(c)
Southern Europe
Spain 38% 8,771 – 23,124 9 – 23 0.5 – 1.3 1.16 9.2 1,194
Greece 44% 6,973 – 15,689 27 – 60 1.6 – 3.7 1.29 8.6 1,198
Italy ~ 54% 13,341 – 24,706 9 – 18 0.5 – 1.0 1.17 12.7 1,824
Portugal Unknown 1,217 – ? 5 – ? 0.1 – ? 1.46 9.7 1,203
Eastern Europe
Hungary 75% 2,094 – 2,792 8 – 11 0.5 – 0.7 1.33 8.5 –
Czech Republic 93% 7,879 – 8,442 30 – 32 1.9 – 2.1 1.16 6.2 –
Russia 63% 4,514 – 7,222 1 – 2 0.1 – 0.1 1.24 – –
Western Europe
Germany ~ 85% 46,132 – 54,565 23 – 28 1.1 – 1.3 1.36 – 2,361
Belgium 66% 9,847 – 14,985 40 – 61 1.7 – 2.7 1.60 15.2 2,050
France 100% 46,800 32 1.4 1.75 8.3 2,043
Netherlands 100% 13,865 35 1.4 1.63 16.9 2,150
Switzerland 100% 4,002 23 1.0 1.47 – 2,853BRO
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recorded
Number
of cycles(a)
Number of cycles 
per 10,000 women
aged 15-49
% of children 
born by assisted 
fertilization(b)
Total fertility rate 
(children
per woman)
Permanent steri-
lity rate of the 
1955 cohort
Health expendi-
ture per head
in 1998 (PPS)(c)
Northern Europe
Denmark 100% 8,409 66 3.0 1.72 12.9 2,132
Finland 100% 7,547 31 2.6 1.70 15.5 1,510
Iceland 100% 383 54 3.9 2.04 – 2,113
Norway 100% 3,643 34 1.7 1.81 13.5 2,452
United Kingdom 100% 33,647 24 1.1 1.71 – 1,510
Sweden 100% 8,381 42 2.4 1.50 12.8 1,732
(a)
 This is the total number of cycles performed in the course of IVF, ICSI, and FER. The ranges are estimates: the lower limit is the number of cycles given in the report,
the upper limit is the number of cycles estimated on the assumption that the centres not reporting have activity levels identical to those of the centres in the report.
(b)
 The estimated number of children born after IVF, ICSI, and FER from a cycle performed in 1998 has been divided by the number of children born in 1999. The num-
ber of children born after IVF, ICSI, and FER has been estimated from data on the number of deliveries and on the distribution of multiple pregnancies (data provided in
the European report). Information on the pregnancy outcomes was lacking for the Netherlands and Belgium, and of poor quality for Switzerland. For these three coun-
tries, the number of children born after IVF, ICSI, and FER has been estimated by assuming that these countries have success rates identical to those of the other 15 coun-
tries. This assumption has also been applied to Spain to estimate the number of children by FER as this country was missing (without any explanation) from some of the
tables in the European report. Furthermore, the European report suffered from inconsistencies in the data for the United Kingdom and consistency assumptions have been
made for this country.
(c)
 PPS (Purchasing Power Standard) is a unit of account independent of national currencies. The conversion of expenditure into PPS enables volume comparisons to be
made.
Sources: European Report on In Vitro Fertilization 1998 (Nygren and Andersen, 2001b), Observatoire démographique européen, Eurostat Yearbook 2002 and Bilan
démographique des pays développés (Sardon, 2002).497
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Figure 1.– Use of assisted fertilization (measured by the number of cycles per 10,000 women aged 15-49 years)
and demographic and economic indicators
Note:  The countries in italics are those for which IVF activity is not known in full and is therefore based on an upper estimate (see Table 3).
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      of the health professionals responsible for gynaecological care, the
number, size and distribution of IVF centres in the country), or by explor-
ing how well these methods are accepted by the population. The financial
cost to couples could be a determining factor. Thus in the United Kingdom,
the decision to attempt a second IVF treatment after an initial failure seems
to be determined not only by perception of its expected success (a percep-
tion based on factors such as the woman’s age, the number of oocytes re-
trieved and the number of embryos transferred during the first IVF attempt)
but also on the couple’s ability to pay for the treatment in a context where
public funding of IVF is extremely limited and variable (Sharma et al.,
2002).
II. IVF: a technique poorly adapted
to severe male factor infertility
1. Measuring the success of IVF treatments
In the literature, the measurement of the IVF success rate is gene-
rally based on the percentage of attempts that have permitted an oocyte re-
trieval leading to a clinical pregnancy, known as the pregnancy rate per
retrieval. From FIVNAT this success rate is estimated at between 20% and
25%. Thus formulated, measurement of success rates may appear simple;
in reality, it involves many difficulties which have been the subject of con-
troversy (Marcus-Steiff, 1990 and 1991; Thibault et al., 1991; Humeau
and Arnal, 1994; Marcus-Steiff, 1994a and 1994b; Tain, 2003b). The preg-
nancy rate per retrieval raises four questions in particular.
First, the population accepted for IVF includes sterile couples, that
is couples with zero probability of conceiving without medical assistance,
but also subfecund couples, who have a non-zero probability of conceiving
“naturally” (Leridon, 1981). To measure the real effectiveness of IVF, it
would be necessary to take into account the existence of what have been
termed the “false IVF babies” (Marcus-Steiff, 1994a), meaning the babies
conceived naturally during the IVF cycle and the babies who could have
been conceived naturally during the cycle if IVF had not been performed.
In other words, the evaluation of success rates should take into account the
probabilities for subfecund couples of conceiving without any medical
treatment (Leridon and Spira, 1984; Leridon, 1990).
Secondly, the pregnancy rate per retrieval does not give an indication
of the proportion of couples obtaining a live birth, since a proportion of
clinical pregnancies end in foetal death (miscarriage, extra-uterine preg-
nancy, still-birth). To obtain an overall measurement of the success of IVF,
it is necessary to estimate the rate of attempts leading to at least one live
birth as a proportion of the total attempts in which a follicular aspiration
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 was practised. This rate is called the “take home baby rate” and stands at
between 15% and 20% of retrievals, on the FIVNAT database(13). An ini-
tial approximation of this rate can be estimated from the delivery rate
(ignoring neonatal mortality). Looking beyond the take home baby rate, a
group of European experts stressed the need for the editorial boards of sci-
entific journals to impose the evaluation of success in terms of a single
foetus pregnancy leading to the birth of a healthy child (ESHRE Campus
Course Report, 2001). This discussion about success indicators (obtaining
at least one live birth or obtaining a single foetus pregnancy leading to the
birth of a healthy child) relates to more general debates about “good clini-
cal practice”, recommending the prevention of multiple pregnancies by
l imi t ing the  number  of  embryos  t ransferred dur ing the  IVF cycle
(Lambert, 2002).
Thirdly, to determine the real success of IVF, we need to measure the
probability of success for the IVF treatment course as a whole (which can
include several attempts), not just for individual IVF cycles. Such an ap-
proach was recently used in an English clinic with 2,056 couples begin-
ning an IVF cycle (Sharma et al., 2002). These couples were observed
until a pregnancy was obtained (n = 879), or until they abandoned the IVF
programme (n = 1,155) or until they had made four unsuccessful attempts
(n = 22). On the basis of this cohort, the authors estimate that after four at-
tempts, 75% of couples have obtained at least one clinical pregnancy and
that 66% have obtained at least one live birth. However, many couples
drop out before these four attempts have been made: after each IVF cycle,
more than 60% of couples who have not obtained a pregnancy give up. For
the cohort under observation, 56% of couples abandoned the IVF pro-
gramme without having obtained a pregnancy, 1% of couples continued
with the treatment up to the fourth unsuccessful attempt, and 43% ob-
tained a pregnancy which in over 80% of cases resulted in a live birth.
Finally, there is marked variation in success rates according to the
characteristics of the couple. In particular, very strong effects are ob-
served for the woman’s age and the man’s spermatic characteristics (Hull
et al., 1992). We will develop this point.
2. Success rates decline as the age
of the woman increases
Figure 2 presents the pregnancy rate per retrieval and the delivery
rate per retrieval as a function of the woman’s age based on FIVNAT data
for the period 1987-1996 (FIVNAT et al., 1990; FIVNAT et al., 1991;
FIVNAT et al., 1997). A marked decline in success rates is observed after
35-37 years, with the rate for attempts that result in a delivery dropping
from 16.4% at 30 years to 9.3% at 40 years and to 2.8% at 45 years.
(13) If the transfer of frozen embryos is included, the success rate increases by 2-3 points.
MEN MEDICALLY ASSISTED TO REPRODUCE 501Because of this, women aged over 35-37 are put on an emergency protocol
that speeds up the procedure. Hence the average time from first consul-
tation to first IVF goes from over a year for women aged under 35 to
6 months for women aged 35 and over, according to a study conducted in
the clinical gynaecology department of a French hospital on a cohort of
women (n=340) consulting for the first time in 1987 or 1991 (Tain, 2002).
3. Success rates decline when the man
has severely abnormal sperm
Success rates also vary as a function of sperm characteristics. IVF
was originally developed to combat female factor infertility associated
with anomalies in the fallopian tubes but its use has been extended to other
female indications and to male and idiopathic indications. The male indi-
cations correspond to spermatic abnormalities: in general, a spermogram
of less than 20 million/ml spermatozoa and/or less than 40% mobile
spermatozoa and/or less than 40% morphologically normal spermatozoa
(Plachot, 1987). With this definition, and using the FIVNAT data, the pro-
portion of IVF performed for purely male indications (i.e. in couples
where the woman has a normal fecundity) increased from 11% to 22%
between 1986 and 1992; over the same period, the proportion of IVF asso-
ciated with a purely female related factor (usually an abnormality of the
fallopian tubes) dropped from 60% to 44%. This increase in male indica-
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Figure 2.– IVF success rate by age of woman, 1987-1996 (%)
Source: Data from FIVNAT (Contraception, Fertilité, Sexualité, 1997, 25(7-8), pp. 503-506, Table 2).
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severe male factor infertility. These failures are related to the lower proba-
bility of achieving fertilization in vitro, whereas the probability that the
embryos obtained will develop seems not to be affected (Giorgetti, 1987;
Tournaye et al., 1992). Thus the fertilization rate (number of embryos ob-
tained divided by the number of oocytes in fertilization) falls from 72% to
18% when the sperm is severely abnormal, i.e. when the proportion of
morphologically normal spermatozoa is below 5% and the number of mo-
tile spermatozoa is below 3 million/ml (Enginsu et al., 1992).
Given this falling off in success rates, the Guide des bonnes pra-
tiques cliniques et biologiques en Assistance Médicale à la Procréation
(Guide to good clinical and biological practice in medically assisted re-
production, CNMBRDP, 1999) indicates that the IVF technique should be
reserved for men with a minimum of 50,000 motile spermatozoa per milli-
litre of sperm. What then are the alternatives in cases of severe male factor
infertility?
III. AID: a poorly accepted technique
The first response from medical science for cases of severe male fac-
tor infertility was artificial insemination with donor sperm. Artificial in-
s e m i n a t i o n  ( A I )  c o n s i s t s  o f  i n t r o d u c i n g  s p e r m  i n t o  t h e  f e m a l e
reproductive tract (cervical canal, cervix, uterus). The inseminated sperm
can be from the husband (AIH) or from a donor (AID). Among couples us-
ing AID, four indications are distinguished: azoospermia (complete ab-
sence of spermatozoa) in 53% of cases, oligospermia (sperm count below
20 million/ml) in 38% of cases, astheno-teratospermia (reduced percent-
age of motile spermatozoa and/or of morphologically normal spermato-
zoa) in 7% of cases, and AID performed for genetic reasons(14) in 2% of
cases(15).
1. Deontological rules common to all
the French centres
AID has a long history: the first successful AID was performed in the
United States in 1884. In 1953, births were obtained using frozen sperma-
tozoa (Netter and Belaisch, 1991). Following on from these technological
(14) AID for genetic reasons is to avoid transmitting to the child a life threatening genetic
disorder or one which would cause a severe handicap (a dominant disorder carried by the father,
for example). See the Guide des bonnes pratiques cliniques et biologiques en Assistance Médi-
cale à la Procréation (CNMBRDP, 1999).
(15) These percentages correspond to the distribution of the indications for AID performed
in France in 1984-1987 (Fédération française des CECOS et al., 1989).
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ated by Professor Georges David, for the freezing and preservation of
spermatozoa, and called the Centres for the Study and Preservation of
Human Sperm (Centres d’étude et de conservation du sperme humain -
CECOS). Subsequently CECOS extended its activity to freezing and pre-
serving eggs and embryos(16), and since then the CECOS acronym has
stood for the Centres for the Study and Preservation of Human Eggs and
Sperm (Centre d’étude et de conservation des œufs et du sperme humain).
The operation of the French “sperm banks” is unique in that the twenty or
so CECOS are organized as a network to form the CECOS Federation(17).
This network makes possible a standardization of procedures between the
different centres and the publication of annual national AID reports. As re-
gards procedures, the French system is based on common deontological
rules originally established by Professor Georges David(18): the donor
must be consenting, be already a father, and have his wife’s agreement;
also, the donation is free and anonymous (Madani-Perret, 1987).
2. Figures for AID in France
The CECOS Federation collects data on AID and publishes them an-
nually(19); a report covering the first fifteen years of CECOS’ activity
(1973-1987) was published in 1989 (Fédération française des CECOS et
al., 1989). The first eight years (1973-1980) were characterized by a large
increase in couples making a first request, followed by a period of stability
with new requests running at around 3,000 a year. The data on AID for the
1986-1998 period are presented in Table 4. In 1990-1992, 20,000 AID cy-
cles were performed each year, resulting in 1,400 deliveries and the birth
of 1,500 children.
In contrast to the data collection system set up for IVF, global or
European reports are not available for AID. The publication of national
AID reports is in fact unique to France, where it is linked to the network
operation of the “sperm banks” (Fédération française des CECOS et al.,
1989). Without equivalent European- and world-level data, we lack the
bases for comparative analyses of this technique.
(16) Medically assisted reproduction by donation of gametes now includes AID and IVF
with a third party donor. IVF with a third party donor can mean a donation of spermatozoa or
oocytes, double donation being illegal (Article L. 152-3, Line 1 of the Public Health Code). Dur-
ing an IVF cycle, if the number of embryos obtained is more than the number of embryos trans-
ferred, the couple can ask for the embryos not transferred to be frozen with a view to performing
a Frozen Embryo Replacement (FER) in a subsequent attempt.
(17) The CECOS Federation has an internet site at the following address:
http://amp-chu-besancon.univ-fcomte.fr/cecos/default.htm.
(18) Since 1994, AID activity is covered by the law on bioethics.
(19) Until 1999, the CECOS Federation’s report was published in Contraception, Fertilité,
Sexualité. Since 2000, it is published in Reproduction Humaine et Hormones. AID data are also
collected for the activity reports produced for the Ministry of Health.
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A survey carried out by INED at the end of 1976 made it possible to
measure the French population’s knowledge of AID at that time. Three
years after the creation of CECOS, 79% respondents reported having
heard of AID(20), 19% had never heard of it, and 2% gave no answer
(Leridon, 1980). Ten years later, virtually everyone (96%) had heard of ar-
tificial insemination (Charbit, 1989). But this widespread awareness of
AID did not necessarily mean that the technique was well accepted.
TABLE 4.– MEDICALLY ASSISTED REPRODUCTION WITH SPERM DONATION, FRANCE,
1986-1998 (ESTIMATES)
Year CECOS
centres(a)
Cycles(b, c) Clinical
pregnancies Deliveries
(d) Children(d)
AID IVF-D
1986 20 23,926 – 1,938 1,550 1,674
1987 20 23,192 1,408 2,204 1,746 1,939
1988 20 21,446 1,864 2,232 1,762 1,976
1989 20 20,004 2,151 2,186 1,720 1,947
1990 20 20,958 2,329 2,377 1,869 2,095
1991 22 20,190 2,313 2,227 1,746 1,981
1992 22 18,260 2,201 2,219 1,757 2,004
1993 22 17,723 2,146 2,167 1,672 1,908
1994 22 16,887 1,921 2,048 1,610 1,860
1995 22 12,510 1,674 1,620 1,309 1,501
1996 22 10,539 1,254 1,359 1,005 1,165
1997 22 9,735 1,182 1,321 937 1,082
1998 23 8,145 1,294 1,351 859 1,001
Total(e) 223,515 21,737 25,249 19,542 22,133
(a)
 The CECOS (Centres for the Study and Preservation of Human Eggs and Sperm) were created in 1973.
Around twenty in number, they are regrouped in the CECOS Federation which coordinates and harmonizes
the operation of the centres, and produces and publishes their annual activity reports.
(b)
 The cycles are divided into AID and IVF-D. AID (artificial insemination with donor sperm) includes
intracervical and intrauterine inseminations. IVF-D (in vitro fertilization with donor sperm) includes con-
ventional IVF, GIFT (Gamete intrafallopian transfer) and ICSI (intracytoplasmic sperm injection).
(c)
 The number of cycles (AID and IVF-D) are taken from the CECOS centres’ activity reports published
annually by the CECOS Federation in issue 7-8 of the journal Contraception, Fertilité, Sexualité between
1987 and 1999. For 1986-1991, the data relate only to the CECOS centres. From 1992 the report also inclu-
des the activities of licensed private clinics, meaning primarily the IFREARES (Institut francophone de
recherche et d’études appliquées à la reproduction et à la sexologie – Francophone Institute for the
Research and Study of Reproduction and Sexology) in Toulouse, which accounts for 1-1.5 % of medically
assisted reproduction activity with donor sperm.
(d)
 The number of deliveries and children are estimated using the hypothesis of an identical success rate for
the pregnancies recorded in the report and those lost to observation. Information on the deliveries and the
children born is only available from 1990. For the period 1986-1989, the number of deliveries and children
born is estimated on the assumption that success rates over this period are identical to those observed over
the 1990-1991 period.
(e)
 For the 1986-1998 period, the 223,515 AID cycles resulted in 19,976 pregnancies, 15,617 deliveries, and
16,916 children. The 21,737 IVF-D cycles resulted in 5,273 pregnancies, 3,925 deliveries, and 5,217 chil-
dren.
Sources: See notes above.
MEN MEDICALLY ASSISTED TO REPRODUCE 505AID raises the question of the acceptance or not of the “donor” prin-
ciple. Two surveys carried out by INED at an interval of eighteen years, in
1976 and 1994, show the state of French public opinion on this subject. In
the 1976 survey, the following question was asked: “do you think this [use
of AID] is a good solution for a couple determined to have a child and that
cannot otherwise have one?”. Among those who had heard of AID, 49%
answered “no”, 41% “yes” and 10% gave no answer (Leridon, 1980). The
people opposed to AID were asked about their reasons for rejecting it;
three reasons together accounted for 61% of the replies: “it is simpler to
adopt a child” (25%), “the child would be only the mother’s and not the
husband’s” (23%), and “the donor might pass on hereditary defects”
(13%). These percentages therefore revealed a mistrust of AID in public
opinion. However, this mistrust could be explained by the relatively recent
creation of CECOS (less than four years earlier) at the time of the survey,
and in 1980, when these figures were published, Henri Leridon concluded:
“It should be noted that this survey is already three years old, and since
public opinion changes quickly in this field there is every reason to think
that it is now more ‘liberal’ than two or three years ago” (p. 158).
What was the position eighteen years later, in 1994, in the “Family
Situations and Employment” survey (see footnote 1)? Respondents were
asked about the medically assisted reproduction methods AID and IVF(21).
After the techniques had been explained to them(22), the respondents were
asked whether for a couple unable to have a child it was better to: 1) use
IVF or adopt a child?; 2) use AID or adopt a child? The answers are pre-
sented in Table 5 according to respondents’ sex and according to whether
they had experienced difficulties in having a child. Regardless of the re-
spondent’s status, IVF is preferred to adoption (49% to 68% in favour of
IVF, against 24% to 35% in favour of adoption) but adoption is preferred
to AID (49% to 55% in favour of adoption, against 24% to 39% in favour
of AID). These responses are revealing of the French population’s very
different attitude towards these two techniques: by comparing these re-
ports, we can conclude that of the medically assisted reproductive tech-
niques, AID is poorly accepted. Despite the difference of formulation
between the 1976 and 1994 surveys, these figures indicate that the French
population remains reticent towards AID, probably because of difficulty in
accepting the idea of sperm donation.
(20) After asking the couple about the adoption solution for sterile couples, AID was men-
tioned in the following terms: “If it is the husband who cannot have a child, it is also possible for
the woman to have a child by using artificial insemination (fertilization without sexual relations).
Today this can be done with the semen of another man, who will remain unknown to the couple,
who receives no payment, and who does it with his wife’s agreement and under medical control.
Have you heard about this method?”.
(21) Unpublished data.
(22) IVF was described thus: “In the laboratory, the woman’s ovum is fertilized with the
husband’s sperm, the embryo is then put back in the mother’s womb”; AID was described as fol-
lows: “The woman is fertilized with another man’s sperm (not her husband’s) after an anonymous
sperm donation”. 
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requested AID during 1985 at the CECOS in Kremlin-Bicêtre (Île-de-
France) and in Rennes (Brittany) (Levy, 1994) brings these difficulties into
sharper focus. In this group, 43% of the couples abandoned the AID proce-
dure. The reasons for this high drop-out rate are hard to establish since in
57% of the cases the couples broke off all contact with CECOS without
giving a reason.
What is the situation in other countries? The law in this field varies
from one country to another, with some countries having forbidden or re-
stricted the use of donor sperm (Hamberger and Janson, 1997). In addi-
tion, in the countries where sperm donation is permitted, a reticence
towards this method has been noted among infertile couples who come up
against society’s negative attitude towards the method(23) (Mahlstedt and
Greenfeld, 1989; Braverman and Corson, 1995). The attitude of close fa-
TABLE 5.– ACCEPTANCE OF IVF AND AID IN FRANCE IN 1994, BY SEX AND EXPERIENCE 
OR NOT OF DIFFICULTIES IN HAVING A CHILD (%)
This table presents the responses to two questions*:
1) For a couple unable to have a child, is it better to: use IVF or adopt a child (assuming that the 
request for adoption would be successful)?
2) For a couple unable to have a child, is it better to: use AID or adopt a child (assuming that the 
request for adoption would be successful)?
Females:
Have never experienced 
difficulties in having a child
Have experienced difficulties
in having a child
IVF AID IVF AID
Use the method 57.5 31.7 66.0 38.5
Adopt a child 31.6 53.3 25.4 49.1
No answer 10.9 15.0 8.6 12.4
100.0 100.0 100.0 100.0
Males:
Have never experienced 
difficulties in having a child
Have experienced difficulties
in having a child
IVF AID IVF AID
Use the method 49.1 24.6 67.8 32.0
Adopt a child 34.3 54.7 24.0 52.2
No answer 16.6 20.7 8.2 15.8
100.0 100.0 100.0 100.0
* In introducing these two questions, the interviewer read out a text to explain each method. IVF was descri-
bed thus: “In the laboratory, the woman’s ovum is fertilized with the husband’s sperm, the embryo is then
put back in the mother’s womb”. AID was described as follows: “The woman is fertilized with another
man’s sperm (not her husband’s) after an anonymous sperm donation”.
Source: INED-INSEE, Family Situations and Employment Survey, 1994.
(23) This negative attitude of society is summed up in the American commander Joshiah
Tatnall’s famous phrase (1859): “Blood is thicker than water”. In particular, a condemnation of
AID by the Roman Catholic and Orthodox Jewish religious authorities is observed (Mahlstedt
and Greenfeld, 1989). According to Françoise Héritier-Augé, the acceptance of “formulas” such
as AID can only occur with the unambiguous support of the law, clear admission into the social
structure, and a matching between the collective imagination and the representation of the person
and their identity (Héritier-Augé, 1985).
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cerned about the bond that will link their child born by AID with its
grandparents (Mahlstedt and Greenfeld, 1989).
Where differences in attitudes towards AID exist they seem to be as-
sociated with the sex of the respondent. Within couples, the decision to be-
gin an AID programme is believed to be taken by the woman in the great
major i ty  of  cases  (Rojo-Moreno  et  a l . ,  1994;  Rojo-Moreno  et  a l . ,
1996)(24). In particular, a sharp difference of attitude between men and
women is observed over the question of secrecy, men being more likely
than women to want to keep the existence of a donor a secret (Braverman
and Corson, 1995). It has been assumed that in keeping it secret, men are
trying to protect their relationship with the child, which is based on a non-
genetic bond. However, this hypothesis may be too simplistic, since a dif-
ference in the attitudes of men and women is also observed over IVF with
oocyte donation, with men more often than their partners wanting to keep
the use of a female donor secret (Braverman and Corson, 1995).
Faced with these difficulties, the medical teams have found that pa-
tients need to be given “time to adjust” before starting the AID procedure
(Mahlstedt and Greenfeld, 1989). For example, the CECOS team of the
Midi-Pyrénées region (La Grave Hospital, Toulouse) considers that once
male sterility has been diagnosed it is necessary to wait at least a year be-
fore starting AID, to leave the man “time to come to terms with the loss of
fecundity” (Mazzone, 2000).
4. AID: a quasi experimental framework for research
in human reproduction
AID has also attracted the attention of researchers working in the
field of human reproduction. Research in this field suffers from numerous
problems, such as selection bias, non-measurable confounding factors, etc.
(Baird et al., 1994; Olsen et al., 1998; Weinberg and Dunson, 2000). Given
these difficulties, medically assisted reproduction constitutes an original
line of approach that enables numerous parameters to be controlled for. It
has, for example, been used in the analysis of AID cycles to study the ef-
fect of maternal age on fecundity. In the case of AID, the male characteris-
tics (i.e. those of the donor) are randomly distributed among the women:
in particular, the donor’s age and the woman’s age are two completely in-
dependent parameters. Moreover, by selecting women whose partner is
azoospermic (i.e. has total sterility), a cohort can be formed of women
who have no chance of conceiving without medical help, thereby avoiding
the problem of selection bias generally encountered in this type of study.
Because of these characteristics AID offers quasi experimental conditions
(24) Similar data for the other techniques are not available and so this result is hard to inter-
pret. 
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two French researchers (Schwartz and Mayaux, 1982) to show that the ef-
fect of a woman’s age was responsible for a slight decline in fecundity af-
ter the age of 30 and a more marked decline after 35. This work confirmed
the existing epidemiological and demographic data while specifying the
effect of maternal age.
The data on IVF could also be used to study the parameters of human
reproduction. Regarding the influence of paternal age, use of data on IVF
with donor oocytes or data on IVF among couples in which the woman is
totally sterile (i.e. with total bilateral tubal sterility) could be an interest-
ing line of research.
IV. ICSI: the development of a medical response
to severe male factor infertility
Between IVF which was ill-adapted and AID which was poorly ac-
cepted, the treatment of severe male factor infertility appeared proble-
matic until the early 1990s (Yovich and Matson, 1995).
1. A new technique
In 1992, a Belgian team announced the birth of four babies (includ-
ing a set of twins) using a new IVF treatment (Palermo et al., 1992). In
conventional IVF treatment, an oocyte and spermatozoa are put together,
and the spermatozoa have to penetrate the oocyte to fertilize it. The new
technique involves taking a single sperm and injecting it directly into the
oocyte by means of a micro-pipette. This technique is known as ICSI
(intracytoplasmic sperm injection). Within IVF, a distinction is now made
between “conventional IVF” and ICSI.
ICSI makes it possible to treat severe male factor infertility, where
semen characteristics include very low sperm count, low sperm motility,
and abnormal sperm morphology (Mansour et al., 1995; Oehninger et al.,
1995). Even with sperm exhibiting major abnormalities, high fertilization
rates (number of embryos obtained divided by number of oocytes in ferti-
lization) of around 71% can be obtained using ICSI (Payne et al., 1994). A
further step was taken in 1995, when Jacques Testart, the “father” of
Amandine, announced the birth of a boy after fertilization of an oocyte
with a spermatid, that is an immature sperm cell (Tesarik et al., 1995).
Since then ICSI has been used on men whose ejaculate contains no sper-
matozoa and from whom spermatozoa and sometimes spermatids are re-
trieved from the testicle, epididymis or spermatic cord(25). According to
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were conceived using spermatozoa obtained by surgical retrieval.
At present, therefore, in vitro fertilization encompasses two main
techniques: “conventional” IVF, a technique developed to treat female fac-
tor infertility; and ICSI, a technique developed to treat severe male factor
infertility. Mixed infertility (female and male) can be treated by one or
other of these techniques depending on the level of sperm abnormality.
2. The diffusion of ICSI
ICSI has been integrated into the data collection system for IVF. In
the FIVNAT prospective survey, 83 ICSI attempts were recorded in 1992.
Since 1992, the number of retrievals reported annually by the centres in-
cludes those carried out for ICSI. Table 2 thus shows a large increase in
the total number of retrievals performed in France, rising from 26,000 in
1992 to 41,000 in 1999. Figure 3 illustrates this development using the
proportion of ICSI in the total recorded retrievals between 1992 and 2000:
in seven years (1994-2000), the proportion of ICSI grew from 7% to 50%.
In numerical terms, this means that of the 41,000 retrievals performed in
France during 1999, 18,000 were for an ICSI and 23,000 for a conven-
tional IVF. In parallel with this, a decline in the number of AID cycles is
observed, from 17,000 in 1994 to 8,000 in 1998 (Table 4). Figure 4 uses
the numbers in Tables 2 and 4 and those in Figure 3 to show the trends in
the number of conventional IVF, ICSI, and AID for the period 1986-1999.
The rapid development of ICSI between 1994 and 1998 is visible, with a
slight decline in the number of conventional IVF and a large decline in the
number of AID occurring over the same period. From a purely economic
point of view, this rapid and widespread adoption of ICSI to the detriment
of AID is paradoxical since AID has a much better cost-effectiveness than
ICSI (Granberg et al., 1996; Philips et al., 2000). The question of relative
cost-effectiveness receives little attention in France where economic crite-
ria do not enter into a couple’s choice, because the cost of infertility treat-
ment is covered by the social security system. The same is not true in
every country. Thus in the United States, the cost of ICSI puts it out of
reach of part of the population who therefore use AID “by default”
(Schover et al., 1996). This has led American physicians to point out that
ICSI is responsible for the emergence of a two-speed medical provision in
the treatment of male factor infertility (Schover et al., 1996).  
(25) The Guide des bonnes pratiques cliniques et biologiques en Assistance Médicale à la
Procréation (CNMBRDP, 1999) specifies that in the current state of knowledge, the use of sper-
matids should only be envisaged in the context of clinical research protocols and after approval
from the Commission nationale de médecine et de biologie de la reproduction et du diagnostic
prénatal (National Commission for Medicine and Biology of Reproduction and Prenatal Diagno-
sis - CNMBRDP).
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Figure 3.– Proportion of conventional IVF and ICSI among in vitro
fertilizations registered in FIVNAT, 1992-2000 (%)
Note: Some centres perform mixed cycles (ICSI + conventional IVF). In this case a proportion of the 
oocytes are fertilized using the conventional IVF technique, and others using the ICSI technique. 
According to the Guide des bonnes pratiques cliniques et biologiques en Assistance Médicale à la Pro-
création (CNMBRDP, 1999), these mixed cycles should remain exceptional and be documented in the 
medical records. Furthermore, if embryos are obtained using both techniques, those obtained through 
conventional IVF should be transferred first. The embryos obtained through conventional IVF and ICSI 
should not be transferred simultaneously (unless justified in the medical records), notably because of 
the need for a correctly documented follow-up of any children that result from this treatment.
Source: FIVNAT.
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Figure 4.– Numbers of conventional IVF, ICSI, and AID performed in France, 
1986-1999
Sources: The annual number of AID (number of insemination cycles) comes from the annual reports of 
the CECOS Federation. The annual number of retrievals (including both conventional IVF and ICSI) 
comes from the centres’ activity reports. The estimate of the number of conventional IVF
and the number of ICSI has been produced by applying the annual proportion of ICSI observed
in the FIVNAT survey.
MEN MEDICALLY ASSISTED TO REPRODUCE 511The diffusion of ICSI can be studied at the worldwide level using the
1995 and 1998 reports. Represented in Figure 5 are the twenty countries
(or groups of countries) for which information was available in both re-
ports(26). In 1998, ICSI as a proportion of IVF varies for these countries
between 30% and 60%. In six years (1992-1998), therefore, this technique
experienced a major growth in the countries taken together, but a high de-
gree of heterogeneity remains: in 1995, the proportion of ICSI ranged
from 1% (in Russia) to 51% (in Belgium). In the majority of countries,
however, use of this technique has progressed along the same linear
trend(27): in those where the proportion of ICSI was around 20% in 1995 it
reached 42% in 1998 (Greece, USA, France, Finland). Some countries di-
verge from this trend: in Russia and the Netherlands, the proportion of
ICSI has increased less, while in Hungary, Italy, and Spain it has increased
more. Spain is the most atypical country in this respect, but the large in-
crease recorded is over four years instead of three as is the case for the
other countries.
(26) Only four of these countries or groups of countries reported their activity in full for
these two years: Finland, Switzerland, Latin America, and Australia and New Zealand. For the
others the proportion of ICSI declared in the centres reporting their activity is assumed to be
identical to that of the centres not reporting their activity.
(27) By excluding the five most atypical countries (Russia, Netherlands, Hungary, Italy, and
Spain), it is estimated that ICSI use in the other fifteen countries has developed on a line whose
slope is given by: proportion of ICSI in 1998 (%)=0.69×proportion of ICSI in 1995 (%)+28.
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Figure 5.– ICSI as a proportion of the IVF performed in twenty countries
in 1995 and 1998 (%)
Source : World reports (see footnote 10).
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over the diffusion of ICSI
These figures illustrating the rapid and widespread diffusion of ICSI
raise questions about the reasons and conditions for the growth of this new
technique. From a medical point of view, the use of ICSI is justified in the
context of strict indications based on severe abnormality of spermatic
characteristics (Khorram et al., 2001). ICSI is also offered when conven-
tional IVF treatment has failed. Nevertheless, the question of the indica-
tions for ICSI is the object of a scientific debate in which the European
review Human Reproduction has taken an active role (Fishel et al., 2000;
Hamilton and Bhattacharya,  2001; Ola  et al . ,  2001; Oehninger and
Gosden, 2002). This debate sets the supporters of an “all ICSI” position,
who advocate extensive recourse to ICSI, even when the man has normal
sperm, against the supporters of ICSI use for more restrictive indications
(male factor infertility, failure of conventional IVF treatment)(28). These
differences of view could partly explain the cross-national variations in
ICSI use. In France, according to FIVNAT data, it is used for male indica-
tions in the large majority of cases (71% in 2000), associated or not with
female related factors. For the remainder, the authors of the FIVNAT re-
port indicate that these are probably ICSI performed after the failure of
IVF attempts.
The supporters of “all ICSI” base their position on research indicat-
ing higher success rates for ICSI than for IVF, while the supporters of a
more restrictive use of ICSI question the validity of those results by point-
ing to methodological problems (in particular problems of selection bias).
The latter also note the high financial cost of ICSI compared with IVF
(around + 30%) and stress the need to remain vigilant over a new tech-
nique whose consequences have still  to be evaluated (Cummins and
Jequier, 1995; Patrizio, 1995; Oehninger, 2001; Oehninger and Gosden,
2002).
4. Questions about the health of children born by ICSI
In evaluating the consequences of ICSI, the issue of the children’s
health is a central concern. This issue had already been raised when IVF
was introduced and the same problems linked to multiple births (and the
risks of foetal and infant mortality that result) arise in the case of ICSI.
But with ICSI three additional questions have to be addressed. Does using
(28) In France, the Guide des bonnes pratiques cliniques et biologiques en Assistance
Médicale à la Procréation (CNMBRDP, 1999) states that ICSI should be reserved for cases
where conventional IVF is impossible or has a very low likelihood of success, particularly in
cases of severe male factor infertility. Moreover the Guide indicates that ICSI can be envisaged in
the case of the failure of conventional IVF. In all cases, the choice of technique and the reasons
for it should be set out clearly in the medical records.
MEN MEDICALLY ASSISTED TO REPRODUCE 513severely abnormal spermatozoa carry a risk for the progeny? Does the
ICSI technique, which is more invasive than conventional IVF (because
the oocyte is penetrated by micro-pipette(29)), increase these risks? Can
circumventing the natural process of sperm selection, by choosing a single
spermatozoon for the fertilization, have harmful consequences? Several
indicators must be used to evaluate the children’s health: the risk of con-
genital malformation, the psychomotor development of the children, and
long-term health status. Various “cohorts” of children born by ICSI have
been formed in Belgium (Bonduelle et al., 1998 and 2002), in England
(Sutcliffe et al., 2001), in Sweden (Wennerholm et al., 2000), in Denmark
(Loft et al., 1999), in France (Epelboin et al., 1998), in Australia (Bowen
et al., 1998; Hansen et al., 2002), and in the United States. Some studies
have obtained reassuring results (Palermo et al., 1996; Bonduelle et al.,
1998 and 2002), but others point to a development retardation in children
conceived by ICSI (Bowen et al., 1998) and an increased risk of congenital
malformation (Kurinczuk and Bower, 1997). Lastly, some authors have put
forward the hypothesis of an increased risk of congenital malformation for
a number of specific pathologies, in particular those of the genital tract in
boys (Wennerholm et al., 2000; Ericson and Kallen, 2001; Sutcliffe et al.,
2001), and anomalies in the number of sex chromosomes (In’t Veld et al.,
1995; Liebaers et al., 1995). These conflicting results reflect the metho-
dological difficulties encountered. These include the small numbers ob-
served (in particular for demonstrating an increased risk of rare congenital
malformations(30)), the high rate of children lost to observation, the com-
position of an adequate case control group, the financial cost of following
a cohort of children born by assisted reproduction, ethical considerations
concerning the monitoring of a cohort of children, and a heterogeneity in
the classificatory systems for malformations (Mitchell, 1997; Hawkins,
Barratt, 1999; Sutcliffe et al., 2001; Sutcliffe, 2002). Faced with these
questions the Guide des bonnes pratiques cliniques et biologiques en As-
sistance Médicale à la Procréation (CNMBRDP, 1999) stresses that prac-
titioners should inform couples about how little is still known about the
effect on children’s health and the possible risks associated with ICSI.
Early in March 2002, a study reopened the debate more broadly by
concluding that children born by conventional IVF and by ICSI are twice
as likely to have a congenital malformation as children born without medi-
cally assisted reproduction (Hansen et al., 2002). A few months later, the
British Medical Journal  published an editorial calling for the prompt cre-
ation of a large-scale prospective study designed to observe the health of
children born by medically assisted reproduction (Sutcliffe, 2002). In
(29) Oocyte damage is observed in around 10% of cases after the injection of the spermato-
zoon. See the Guide des bonnes pratiques cliniques et biologiques en Assistance Médicale à la
Procréation (CNMBRDP, 1999).
(30) If a congenital malformation affects 1 child in 1,000, then 20,000 children born by
ICSI and 20,000 case control children would have to be observed to demonstrate a doubling of
the risk (Hawkins et al., 1999).
514 É. de LA ROCHEBROCHARDFrance the National Consultative Bioethics Committee (CCN)(31), in its
75th recommendation published in December 2002 (Comité consultatif na-
tional d'éthique pour les sciences de la vie et de la santé (CNNE), 2002),
noted the need for improved evaluation of the consequences of ICSI on
children’s health but also stressed that establishing a cohort raised ethical
problems, with concerns over the risk of stigmatizing the children and res-
pect for individual freedom (requiring follow-up to be based on voluntary
participation). The first studies on the health of children born by ICSI will
probably look at the risks of congenital malformation and the children’s
psychomotor development. In the longer term, however, other questions
will have to be addressed. Twenty years from now, the first children born
by ICSI will be 30 years old. Their fertility will then have to be monitored,
with particular attention being paid to the fecundity of boys whose fathers
had severely impaired fecundity(32). Are sons born by ICSI at greater risk
of becoming in turn men medically assisted to reproduce?
5. Questions over the health of women
Questions have also been raised about the consequences of ICSI for
women’s health. In reality, at issue here is the technique of in vitro fertili-
zation in general, be it conventional IVF or ICSI (Laborie, 1994b). In the
context of ICSI, however, the concern is over the ethics and consistency of
a medical treatment in which the risks of the technique are borne by the
woman, even though her own fecundity is unimpaired and the infecundity
comes from her partner (Athéa, 1990). Although the issue of treating male
factor infertility in the woman’s body(33) arose with AID, the potential
health consequences for the woman are greater with ICSI, and so too are
the questions raised. It is interesting to note that the spouses of infertile
men, even when they are aware of these risks, show the same preference
for ICSI as the men when required to chose between ICSI and AID(34)
(Schover et al., 1996).
Where women’s health is concerned, the issue of mental health must
also be addressed. Infertility is a source of deep psychological distress and
studies have shown that in this area the dominant factor is not the contri-
bution of the individual to the infertility problem (female factor and/or
male factor infertility) but the sex of the individual (Greil, 1997). Even in
(31) The National Consultative Bioethics Committee (CCN) has a website where these
recommendations are published: http://www.ccne-ethique.fr
(32) This issue arises more specifically in the case of male infertility, since it is thought that
this may be of mainly genetic origin, transmitted by the father but also by the mother (Meschede
et al., 2000; Ford, 2001). The birth of children from infertile men by medically assisted reproduc-
tion raises questions over the transmission of this infertility to the next generation.
(33) This relationship between the body (particularly the female body) and assisted medical
reproduction techniques has been the subject of sociological analyses (Rouch, 1995; Oudshoorn,
2000; Tain, 2003a).
(34) However, women more often than their husbands mention concerns about their health
(Schover et al., 1996).
MEN MEDICALLY ASSISTED TO REPRODUCE 515cases of male factor infertility, women experience greater psychological
distress than their partners. The burden of the techniques (AID, IVF and
ICSI) falls mainly on women and could be a determining element in ex-
plaining this greater female distress (Wright et al., 1991). Other explana-
tions, more sociological, have also been put forward, with the hypothesis
that reproduction is still the domain of women (Héritier-Augé, 1985;
Wright et al., 1991), even though we now know that infertility is not al-
ways due to female related factors. Lastly, in this area of mental health,
managing a chronic stress such as infertility apparently differs by sex.
Women tend to respond to it by “brooding” on the situation (thus develop-
ing reactions of stress and distress), while the reaction of men is to ignore
and deny the problem by becoming involved in other fields (Wright et al.,
1991).
Conclusion
For a long time, the medical profession considered that the treatment
of male factor infertility was limited, particularly compared with the suc-
cess achieved with female factor infertility (Hamberger and Janson, 1997).
In cases of severe male factor infertility, the use of donor sperm was ini-
tially the only effective technique of medically assisted reproduction. With
the development of ICSI, a revolution in the medical treatment of male
factor infertility has thus been observed over the last decade. An infertile
man can now conceive a child in vitro that is genetically his. The rapid and
widespread diffusion of ICSI reflects the success of this medically assisted
reproduction technique developed to treat male factor infertility, but its
use raises a number of questions. Its limitations are economic (the high
cost of ICSI), ethical (treatment of male factor infertility in the woman’s
body) and health-related, with in particular questions over both the long-
and short-term health of the children born by ICSI. In the face of these is-
sues, we need to remember that other medical revolutions could dramati-
cally alter the medical approach to male factor infertility in the future, at
the level both of diagnosis and of treatment (Ford, 2001).
Acknowledgements. I am grateful to Jacques de Mouzon (INSERM) who for over a
year has overseen my work with data on medically assisted reproduction; the writing
of this article owes much to this collaboration. My thanks also go to the FIVNAT
team that manages, collects and inputs the survey data, without whom this analysis
of assisted fertilization in France would not have been possible.
Thanks to Henri Leridon (INED-INSERM), Alfred Spira (AP-HP) and
Annie Bachelot (INSERM) for their constructive comments on early drafts of this
article. Finally, I am grateful to Loïc Desquilbet for his technical assistance in pro-
ducing the graphs on the European and world data.
516 É. de LA ROCHEBROCHARDREFERENCES
ATHÉA N., 1994, “La stérilité : une entité mal définie”, in J. Testart (ed.), Le magasin des enfants,
Gallimard (Coll. Folio), pp. 47-95.
BAIRD D.D., WEINBERG C.R., SCHWINGL P., WILCOX A.J., 1994, “Selection bias associated with
contraceptive practice in time-to-pregnancy studies”, Annals of the New York Academy of
Sciences, 709, pp. 156-164.
BONDUELLE M., JORIS H., HOFMANS K., LIEBAERS I., VAN STEIRTEGHEM A., 1998, “Mental deve-
lopment of 201 ICSI children at 2 years of age”, The Lancet, 351(9115), p. 1553.
BONDUELLE M., LIEBAERS I., DEKETELAERE V., DERDE M.P., CAMUS M., DEVROEY P.,
VAN STEIRTEGHEM A., 2002, “Neonatal data on a cohort of 2,889 infants born after ICSI
(1991-1999) and of 2,995 infants born after IVF (1983-1999)”, Human Reproduction,
17(3), pp. 671-694.
BOWEN J.R., GIBSON F.L., LESLIE G.I., SAUNDERS D.M., 1998, “Medical and developmental out-
come at 1 year for children conceived by intracytoplasmic sperm injection”, The Lancet,
351(9115), pp. 1529-1534.
BRAVERMAN A.M., CORSON S.L., 1995, “Factors related to preferences in gamete donor sources”,
Fertility and Sterility, 63(3), pp. 543-549.
BREART G., MOUZON J. de, 1995, “AMP vigilance”, Bulletin de l’Académie nationale de méde-
cine, 179(8), pp. 1759-1764.
CARLSEN E., GIWERCMAN A., KEIDING N., SKAKKEBAEK N.E., 1992, “Evidence for decreasing
quality of semen during past 50 years”, British Medical Journal, 305(6854), pp. 609-613.
CHARBIT Y., 1989, “L’opinion sur la politique démographique, la nuptialité et les nouvelles tech-
niques de procréation en mai 1987”, Population, 44(6), pp. 1159-1187.
CNMBRDP (Commission nationale de médecine et de biologie de la reproduction et du diagnos-
tic prénatal), 1999, Guide des bonnes pratiques cliniques et biologiques en Assistance
Médicale à la Procréation, Journal Officiel de la République Française 28 February 1999
(decree of 12 January 1999).
COMITÉ CONSULTATIF NATIONAL D’ETHIQUE POUR LES SCIENCES DE LA VIE ET DE LA SANTÉ (CNNE),
2002, Questions éthiques soulevées par le développement de l’ICSI, CNNE Opinion, 75,
11 p.
CROSIGNANI P.G., RUBIN B., ACOSTA A., BENAGIONO G., COLLINS J., DICZFALUSY E., FARLEY T.,
HARGREAVE T., TARLATZIS B., VAN STEIRTEGHEM A., WALTERS E., DIEDRICH K., RAGNI G.,
1994, “Male sterility and subfertility: guidelines for management. The ESHRE Capri
Workshop Group”, Human Reproduction, 9(7), pp. 1260-1264.
CUMMINS J.M., JEQUIER A.M., 1995, “Concerns and recommendations for intracytoplasmic
sperm injection (ICSI) treatment”, Human Reproduction, 10(Suppl 1), pp. 138-143.
DAGUET F., 2002, Un siècle de fécondité française : caractéristiques et évolution de la fécondité
de 1901 à 1999 (INSEE Résultats, 8),  305 p.
DEHAN M., 1998, “La part des traitements de l’infertilité dans la grande prématurité en France.
L’avis du néonatologiste”, Contraception, Fertilité, Sexualité, 26(7-8), pp. 512-516.
ENGINSU M.E., PIETERS M.H., DUMOULIN J.C., EVERS J.L., GERAEDTS J.P., 1992, “Male factor as
determinant of in-vitro fertilization outcome”, Human Reproduction, 7(8), pp. 1136-
1140.
EPELBOIN S., BLONDEAU M.-A., 1989, “Grossesses multiples après procréation médicalement
assistée : devenir obstétrical”, Contraception, Fertilité, Sexualité, 17(7-8), pp. 756-758.
EPELBOIN S., COFFINEAU A., LUCAS H., DE MEDEIROS N., FRANCOUAL C., GOUJEARD J., POIROT C.,
IZARD V., THIOUNN N., ABIRACHED F., QUANTIN P., DOUARD S., VENTADOUR M.,
JOUANNET P., ZORN J.R., WOLF J.P., 1998, “Exhaustive assessment of 150 post-ICSI
pregnancies and subsequent children’s development (1994-1996)”, Human Reproduc-
tion, 13 (Abstract book), pp. 190-191.
ERICSON A., KALLEN B., 2001, “Congenital malformations in infants born after IVF: a
population-based study”, Human Reproduction, 16(3), pp. 504-509.
ESHRE CAMPUS COURSE REPORT, 2001, “Prevention of twin pregnancies after IVF/ICSI by single
embryo transfer”, Human Reproduction, 16(4), pp. 790-800.
FÉDÉRATION FRANÇAISE DES CECOS, LE LANNOU D., LANSAC J., 1989, “Artificial procreation with
frozen donor semen: experience of the French Federation CECOS”, Human Reproduc-
tion, 4(7), pp. 757-761.
MEN MEDICALLY ASSISTED TO REPRODUCE 517FISHEL S., ASLAM I., LISI F., RINALDI L., TIMSON J., JACOBSON M., GOBETZ L., GREEN S.,
CAMPBELL A., LISI R., 2000, “Should ICSI be the treatment of choice for all cases of in-
vitro conception?”, Human Reproduction, 15(6), pp. 1278-1283.
FIVNAT, PIETTE C., MOUZON J. de, BACHELOT A., SPIRA A., 1990, “In-vitro fertilization: influen-
ce of women’s age on pregnancy rates”, Human Reproduction, 5(1), pp. 56-59.
FIVNAT, MOUZON J. de, BACHELOT A., 1991, “Âge des femmes et fécondation in vitro”,
Contraception, Fertilité, Sexualité, 19(7-8), pp. 567-569.
FIVNAT, 1993, “French National IVF Registry: analysis of 1986 to 1990 data”, Fertility and Ste-
rility, 59(3), pp. 587-595.
FIVNAT, 1995, “Pregnancies and births resulting from in vitro fertilization: French national re-
gistry, analysis of data 1986 to 1990”, Fertility and Sterility, 64(4), pp. 746-756.
FIVNAT, BELAISCH-ALLART J., MOUZON J. de, BACHELOT A., DE VECCHI A., RENON C., 1997,
“Age et PMA”, Contraception, Fertilité, Sexualité, 25(7-8), pp. 503-506.
FORD W.C., 2001, “Biological mechanisms of male infertility”, The Lancet, 357(9264),
pp. 1223-1224.
GARCEAU L., HENDERSON J., DAVIS L.J., PETROU S., HENDERSON L.R., MCVEIGH E., BARLOW D.H.,
DAVIDSON L.L., 2002, “Economic implications of assisted reproductive techniques: a sys-
tematic review”, Human Reproduction, 17(12), pp. 3090-3109.
GIORGETTI C., 1987, “Spermogramme et chances de succès de la fécondation in vitro”, Contra-
ception, Fertilité, Sexualité, 15(7-8), p. 703.
GRANBERG M., WIKLAND M., HAMBERGER L., 1996, “Cost-effectiveness of intracytoplasmic
sperm injection in comparison with donor insemination”, Acta Obstetricia et Gynecolo-
gica Scandinavica, 75(8), pp. 734-737.
GREIL A.L., 1997, “Infertility and psychological distress: a critical review of the literature”, So-
cial Science & Medicine, 45(11), pp. 1679-1704.
HAMBERGER L., JANSON P.O., 1997, “Global importance of infertility and its treatment: role of
fertility technologies”, International Journal of Gynaecology and Obstetrics, 58(1),
pp. 149-158.
HAMILTON M., BHATTACHARYA S., 2001, “Should ICSI be the treatment for all cases of in-vitro
conception?”, Human Reproduction, 16(4), pp. 801-802.
HANSEN M., KURINCZUK J.J., BOWER C., WEBB S., 2002, “The risk of major birth defects after
intracytoplasmic sperm injection and in vitro fertilization”, New England Journal of Me-
dicine, 346(10), pp. 725-730.
HAWKINS M.M., BARRATT C.L., 1999, “Intracytoplasmic sperm injection”, Science, 286(5437),
pp. 51-52.
HAWKINS M.M., BARRATT C.L., SUTCLIFFE A.G., COOKE I.D., 1999, “Male infertility and in-
creased risk of diseases in future generations”, The Lancet, 354(9193), pp. 1906-1907.
HÉRITIER-AUGÉ F., 1985, “La cuisse de Jupiter : réflexions sur les nouveaux modes de procréa-
tion”, L’Homme, 25(94), pp. 5-22 (reprinted in F. Héritier, 1996, Masculin – Féminin. La
pensée de la différence, Paris, Odile Jacob, pp. 253-275).
HULL M.G., EDDOWES H.A., FAHY U., ABUZEID M.I., MILLS M.S., CAHILL D.J., FLEMING C.F.,
WARDLE P.G., FORD W.C., MCDERMOTT A., 1992, “Expectations of assisted conception for
infertility”, British Medical Journal, 304(6840), pp. 1465-1469.
HUMEAU C., ARNAL F., 1994, Les médecines de procréation : comptes et mécomptes de la fé-
condation in vitro, Éditions Odile Jacob, 407 p.
IN’T VELD P., BRANDENBURG H., VERHOEFF A., DHONT M., LOS F., 1995, “Sex chromosomal ab-
normalities and intracytoplasmic sperm injection”, The Lancet, 346(8977), pp. 773.
IRVINE D.S., 1998, “Epidemiology and aetiology of male infertility”, Human Reproduction,
13(Suppl 1), pp. 33-44.
KHORRAM O., PATRIZIO P., WANG C., SWERDLOFF R., 2001, “Reproductive technologies for male
infertility”, Journal of Clinical Endocrinology and Metabolism, 86(6), pp. 2373-2379.
KURINCZUK J.J., BOWER C., 1997, “Birth defects in infants conceived by intracytoplasmic sperm
injection: an alternative interpretation”, British Medical Journal, 315(7118), pp. 1260-
1265 ; discussion 1265-1266.
LABORIE F., 1994a, “Nouvelles technologies de la reproduction (NTR) : risques pour la santé des
enfants”, in Les modes de régulation de la reproduction humaine : incidences sur la fé-
condité et la santé, AIDELF International Conference, Delphes, 1992, pp. 771-777.
LABORIE F., 1994b, “Nouvelles technologies de la reproduction (NTR) : risques pour la santé des
femmes”, in Les modes de régulation de la reproduction humaine : incidences sur la fé-
condité et la santé, AIDELF International Conference, Delphes, 1992, pp. 757-770.
518 É. de LA ROCHEBROCHARDLAMBERT R.D., 2002, “Safety issues in assisted reproduction technology: The children of assis-
ted reproduction confront the responsible conduct of assisted reproductive technologies”,
Human Reproduction, 17(12), pp. 3011-3015.
LERIDON H., 1980, “La stérilité et l’insémination artificielle par donneur dans l’opinion”,
Contraception, Fertilité, Sexualité, 8(2), pp. 153-158.
LERIDON H., 1981, “Fécondité, fertilité, stérilité : problèmes de terminologie”, in A. Spira,
P. Jouannet (eds.), Facteurs de la fertilité humaine (avec référence particulière au sexe
masculin), INSERM Conference, Cargèse 21-23 September 1981, pp. 17-30.
LERIDON H., SPIRA A., 1984, “Problems in measuring the effectiveness of infertility therapy”,
Fertility and Sterility, 41(4), pp. 580-586.
LERIDON H., CHARBIT Y., COLLOMB P., SARDON J.-P., TOULEMON L. (eds.), 1987, La seconde ré-
volution contraceptive. La régulation des naissances en France de 1950 à 1985 (Travaux
et Documents, Cahier n° 117), INED, 380 p.
LERIDON H., 1990, “De la procréation naturelle à la procréation médicalement assistée : le point
de vue du démographe”, Journal de la Société de Statistique de Paris, 131(2), pp. 3-23.
LERIDON H., 1992, “Sterility and subfecundity: from silence to impatience?”, Population: An En-
glish Selection, 4, pp. 35-54.
LERIDON H., OUSTRY P., BAJOS N., ÉQUIPE COCON, 2002, “La médicalisation croissante de la
contraception en France”, Population et Societes, 381.
LÉVY C., 1994, “Aperçu d’une population ayant eu recours à la procréation médicalement assis-
tée”, in Les modes de régulation de la reproduction humaine : incidences sur la fécondité
et la santé, AIDELF International Conference, Delphes, 1992, pp. 353-364.
LIEBAERS I., BONDUELLE M., VAN ASSCHE E., DEVROEY P., VAN STEIRTEGHEM A., 1995, “Sex chro-
mosome abnormalities after intracytoplasmic sperm injection”, The Lancet, 346(8982),
pp. 1095.
LOFT A., PETERSEN K., ERB K., MIKKELSEN A.L., GRINSTED J., HALD F., HINDKJAER J.,
NIELSEN K.M., LUNDSTROM P., GABRIELSEN A., LENZ S., HORNNES P., ZIEBE S.,
EJDRUP H.B., LINDHARD A., ZHOU Y., NYBOE ANDERSEN A., 1999, “A Danish national co-
hort of 730 infants born after intracytoplasmic sperm injection (ICSI) 1994-1997”,
Human Reproduction, 14(8), pp. 2143-2148.
MADANI-PERRET F.Z., 1987, “Le don de sperme : la règle de l’anonymat”, Contraception,
Fertilité, Sexualité, 15(7-8), pp. 678-680.
MAHLSTEDT P.P., GREENFELD D.A., 1989, “Assisted reproductive technology with donor gametes:
the need for patient preparation”, Fertility and Sterility, 52(6), pp. 908-914.
MANSOUR R.T., ABOULGHAR M.A., SEROUR G.I., AMIN Y.M., RAMZI A.M., 1995, “The effect of
sperm parameters on the outcome of intracytoplasmic sperm injection”, Fertility and Ste-
rility, 64(5), pp. 982-986.
MARCUS-STEIFF J., 1990, “Les taux de succès de la FIV, fausses transparences et vrais menson-
ges”, La Recherche, 21(225), pp. 1300-1312.
MARCUS-STEIFF J., 1991, “La controverse sur les taux de ‘succès’ de la FIV”, La Recherche,
22(231), pp. 524-529.
MARCUS-STEIFF J., 1994a, “La mesure des taux de ‘succès’ de la FIV”, in Les modes de ré-
gulation de la reproduction humaine : incidences sur la fécondité et la santé, AIDELF
International Conference, Delphes, 1992, pp. 637-647.
MARCUS-STEIFF J., 1994b, “Les procréations artificielles : inventaire des techniques, effets sur la
natalité”, in Les modes de régulation de la reproduction humaine : incidences sur la fé-
condité et la santé, AIDELF International Conference, Delphes, 1992, pp. 365-385.
MAZZONE J.-C., 2000, “L’anonymat garant de la levée du secret de la conception dans l’I.A.D.”,
Reproduction humaine et hormones, 13(5), pp. 528-531.
MESCHEDE D., LEMCKE B., BEHRE H.M., DE GEYTER C., NIESCHLAG E., HORST J., 2000, “Cluster-
ing of male infertility in the families of couples treated with intracytoplasmic sperm in-
jection”, Human Reproduction, 15(7), pp. 1604-1608.
MITCHELL A.A., 1997, “Intracytoplasmic sperm injection: offering hope for a term pregnancy
and a healthy child?”, British Medical Journal, 315(7118), pp. 1245-1246.
MOUZON J. de, SPIRA A., SCHWARTZ D., 1988, “A prospective study of the relation between smo-
king and fertility”, International Journal of Epidemiology, 17(2), pp. 378-384.
MOUZON J. de, BACHELOT A., SPIRA A., 1993, “Establishing a national in vitro fertilization regis-
try: methodological problems and analysis of success rates”, Statistics in Medicine,
12(1), pp. 39-50.
MEN MEDICALLY ASSISTED TO REPRODUCE 519MOUZON J. de, THONNEAU P., SPIRA A., MULTIGNER L., 1996, “Declining sperm count. Semen
quality has declined among men born in France since 1950”, British Medical Journal,
313(7048), p. 43 ; discussion 44-45.
NETTER A., BELAISCH J., 1991, “Histoire de la procréation médicalement assistée”, Reproduction
humaine et hormones, 3(5), pp. 283-293.
NYGREN K.G., ANDERSEN A.N., 2001a, “Assisted reproductive technology in Europe, 1997. Re-
sults generated from European registers by ESHRE. European IVF-Monitoring Program-
me (EIM), for the European Society of Human Reproduction and Embryology
(ESHRE)”, Human Reproduction, 16(2), pp. 384-391.
NYGREN K.G., ANDERSEN A.N., 2001b, “Assisted reproductive technology in Europe, 1998. Re-
sults generated from European registers by ESHRE”, Human Reproduction, 16(11),
pp. 2459-2471.
OEHNINGER S., VEECK L., LANZENDORF S., MALONEY M., TONER J., MUASHER S., 1995, “Intracy-
toplasmic sperm injection: achievement of high pregnancy rates in couples with severe
male factor infertility is dependent primarily upon female and not male factors”, Fertility
and Sterility, 64(5), pp. 977-981.
OEHNINGER S., 2001, “Place of intracytoplasmic sperm injection in management of male infer-
tility”, The Lancet, 357(9274), pp. 2068-2069.
OEHNINGER S., GOSDEN R.G., 2002, “Should ICSI be the treatment of choice for all cases of in-
vitro conception?: No, not in light of the scientific data”, Human Reproduction, 17 (9),
pp. 2237-2242.
OLA B., AFNAN M., SHARIF K., PAPAIOANNOU S., HAMMADIEH N., BARRATT C.L., 2001, “Should
ICSI be the treatment of choice for all cases of in-vitro conception? Considerations of
fertilization and embryo development, cost effectiveness and safety”, Human Reproduc-
tion, 16(12), pp. 2485-2490.
OLIVENNES F., 2001, “Grossesse gémellaire après traitement de l’infertilité : échec ou succès ?”,
Gynécologie obstétrique & fertilité, 29(3), pp. 257-260.
OLSEN J., JUUL S., BASSO O., 1998, “Measuring time to pregnancy. Methodological issues to con-
sider”, Human Reproduction, 13(7), pp. 1751-1753.
OUDSHOORN N., 2000, “Au sujet des corps, des techniques et des féminismes”, in D. Gardey,
I. Löwy (eds.), L’invention du naturel : les sciences et la fabrication du féminin et du
masculin. Histoire des sciences, des techniques et de la médecine, Paris, Éditions des
archives contemporaines, pp. 31-44.
PALERMO G., JORIS H., DEVROEY P., VAN STEIRTEGHEM A.C., 1992, “Pregnancies after intracyto-
plasmic injection of single spermatozoon into an oocyte”, The Lancet, 340(8810), pp. 17-
18.
PALERMO G.D., COLOMBERO L.T., SCHATTMAN G.L., DAVIS O.K., ROSENWAKS Z., 1996, “Evolution
of pregnancies and initial follow-up of newborns delivered after intracytoplasmic sperm
injection”, Journal of American Medical Association, 276(23), pp. 1893-1897.
PAPIERNIK E., MOUZON J. de, 2002, “Triplet pregnancies from French IVF centers: 1986-98”, in
L.G. Keith, I. Blickstein (eds.), Triplet pregnancies and their consequences, Parthenon
Publishing Group, pp. 45-54.
PATRIZIO P., 1995, “Intracytoplasmic sperm injection (ICSI): potential genetic concerns”, Human
Reproduction, 10(10), pp. 2520-2523.
PAYNE D., FLAHERTY S.P., JEFFREY R., WARNES G.M., MATTHEWS C.D., 1994, “Successful treat-
ment of severe male factor infertility in 100 consecutive cycles using intracytoplasmic
sperm injection”, Human Reproduction, 9(11), pp. 2051-2057.
PHILIPS Z., BARRAZA-LLORENS M., POSNETT J., 2000, “Evaluation of the relative cost-effective-
ness of treatments for infertility in the UK”, Human Reproduction, 15(1), pp. 95-106.
PLACHOT M., 1987, “Les indications masculines de la FIV. Enquête nationale”, Contraception,
Fertilité, Sexualité, 15(7-8), pp. 699-700.
ROJO MORENO J., VALDEMORO GARCIA C., GARCIA MERITA M.L., TORTAJADA MARTINEZ M.G.,
1994, “Personality characteristics’ analysis in couples undergoing artificial insemina-
tion”, Human Reproduction, 9(1), pp. 172-175.
ROJO MORENO J., VALDEMORO C., GARCIA MERITA M.L., TORTAJADA M., 1996, “Analysis of the
attitudes and emotional processes in couples undergoing artificial insemination by do-
nor”, Human Reproduction, 11(2), pp. 294-299.
ROUCH H., 1995, “Les nouvelles techniques de reproduction : vers l’indifférenciation
sexuelle ?”, in  A. Ducros, M. Panoff (eds.), La frontière des sexes (Le Sociologue), Paris,
Puf, pp. 251-269.
520 É. de LA ROCHEBROCHARDSARDON J.-P., 2002, “Recent demographic trends in the developed countries”, Population-E,
57(1), pp. 111-156.
SCHOVER L.R., THOMAS A.J., MILLER K.F., FALCONE T., ATTARAN M., GOLDBERG J., 1996, “Pre-
ferences for intracytoplasmic sperm injection versus donor insemination in severe male
factor infertility: a preliminary report”, Human Reproduction, 11(11), pp. 2461-2464.
SCHWARTZ D., MAYAUX M.J., 1982, “Female fecundity as a function of age: results of artificial
insemination in 2,193 nulliparous women with azoospermic husbands. Federation
CECOS”, New England Journal of Medicine, 306(7), pp. 404-406.
SHARMA V., ALLGAR V., RAJKHOWA M., 2002, “Factors influencing the cumulative conception rate
and discontinuation of in vitro fertilization treatment for infertility”, Fertility and Steri-
lity, 78(1), pp. 40-46.
SPIRA A., 1986, “Epidemiology of human reproduction”, Human Reproduction, 1(2), pp. 111-
115.
STEPTOE P.C., EDWARDS R.G., 1978, “Birth after the reimplantation of a human embryo”, The
Lancet, 2(8085), pp. 366.
SUTCLIFFE A.G., TAYLOR B., SAUNDERS K., THORNTON S., LIEBERMAN B.A., GRUDZINSKAS J.G.,
2001, “Outcome in the second year of life after in-vitro fertilisation by intracytoplasmic
sperm injection: a UK case-control study”, The Lancet, 357(9274), pp. 2080-2084.
SUTCLIFFE A.G., 2002, “Health risks in babies born after assisted reproduction”, British Medical
Journal, 325(7356), pp. 117-118.
TAIN L., 2002, “The hospital, the woman and the physician: the construction of in vitro fertili-
zation trajectories”, Population-E, 57(2), pp. 373-404.
TAIN L., 2003a, “Corps reproducteur et techniques procréatives : images, brouillages, montages
et remue-ménage”, Cahiers du Genre, 34 (special issue “La distinction entre science et
genre : une histoire entre biologie et culture”), I. Löwy, H. Rouch (eds.), pp. 171-192.
TAIN L., 2003b, “Évaluation et expansion des techniques de reproduction : des succès pour
qui ?”, Santé publique et Sciences sociales, 10, forthcoming.
TESARIK J., MENDOZA C., TESTART J., 1995, “Viable embryos from injection of round spermatids
into oocytes”, New England Journal of Medicine, 333(8), p. 525.
TESTART J., FRYDMAN R., 1982, “Naissance à terme après implantation intra-utérine d’un em-
bryon obtenu par fécondation in vitro”, Journal de Gynécologie, Obstétrique et Biologie
de la Reproduction, 11(7), pp. 855-859.
THIBAULT C., COHEN J., ZORN J.R., CEDARD L., HEDON B., SALAT-BAROUX J., POULY J.-L.,
BUVAT J., BRUNETTI P.-M., BLANC F., RELIER J.-P., JOUHET P., MARCUS-STEIFF J., 1991, “La
controverse sur les taux de succès de la FIV”, La Recherche, 22(231), pp. 524-529.
THONNEAU P., MARCHAND S., TALLEC A., FERIAL M.L., DUCOT B., LANSAC J., LOPES P.,
TABASTE J.-M., SPIRA A., 1991, “Incidence and main causes of infertility in a resident po-
pulation (1,850,000) of three French regions (1988-1989)”, Human Reproduction, 6(6),
pp. 811-816.
TOURNAYE H., DEVROEY P., CAMUS M., STAESSEN C., BOLLEN N., SMITZ J., VAN STEIRTEGHEM
A.C., 1992, “Comparison of in-vitro fertilization in male and tubal infertility: a 3 year
survey”, Human Reproduction, 7(2), pp. 218-222.
VAN DEN EEDE B., 1995, “Investigation and treatment of infertile couples: ESHRE guidelines
for good clinical and laboratory practice. European Society of Human Reproduction and
Embryology”, Human Reproduction, 10(5), pp. 1246-1271.
VAYENA E., ROWE P.J., PETERSON H.B., 2002, “Assisted reproductive technology in developing
countries: why should we care ?”, Fertility and Sterility, 78(1), pp. 13-15.
WEINBERG C.R., DUNSON D.B., 2000, “Some issues in assessing human fertility”, Journal of the
American Statistical Association, 95, pp. 300-303.
WENNERHOLM U.B., BERGH C., HAMBERGER L., LUNDIN K., NILSSON L., WIKLAND M., KALLEN B.,
2000, “Incidence of congenital malformations in children born after ICSI”, Human
Reproduction, 15(4), pp. 944-948.
WRIGHT J., DUCHESNE C., SABOURIN S., BISSONNETTE F., BENOIT J., GIRARD Y., 1991, “Psychoso-
cial distress and infertility: men and women respond differently”, Fertility and Sterility,
55(1), pp. 100-108.
YOVICH J.L., MATSON P.L., 1995, “Male subfertility: concepts in 1995”, Human Reproduction,
10(Suppl 1), pp. 3-9.
MEN MEDICALLY ASSISTED TO REPRODUCE 521LA ROCHEBROCHARD Élise de.– Men Medically Assisted to Reproduce:  AID, IVF, and ICSI, an
Assessment of the Revolution in the Medical Treatment of Male Factor Infertility
In response to involuntary infertility, which affects 15% to 20% of couples, the tech-
niques of in vitro fertilization (IVF) have been developed. Between 1982 and 2000, 85,000 chil-
dren were born in France thanks to IVF (estimates based on combined analysis of the FIVNAT
survey and administrative data). Five world reports and two European reports have been pro-
duced on IVF, but their use remains limited by incomplete data for regions such as southern and
eastern Europe. The success rates with IVF are around 15% to 20% of pregnancies obtained per
retrieval. However, these rates decline rapidly as the woman’s age rises and when the man’s
sperm has severe abnormalities. In cases of severe male factor infertility, artificial insemination
by donor (AID) was for long the only medical solution, but it raises the problem of accepting
sperm from a donor. Since 1992, a new IVF technique, intracytoplasmic sperm injection (ICSI)
is available. This technique has been widely adopted in France and in many other countries: in
1998 it represented 30% to 60% of assisted fertilizations. Despite this large development, nu-
merous questions remain concerning the consequences of the technique, particularly regarding
the short- and long-term health of children conceived by ICSI.
LA ROCHEBROCHARD Élise de.– Des hommes médicalement assistés pour procréer : IAD,
FIV, ICSI, bilan d’une révolution dans la prise en charge médicale de l’infertili-
té masculine
Face aux problèmes d’infertilité, qui concernent 15 % à 20 % des couples, on a assisté
au développement des techniques de fécondation in vitro (FIV). Entre 1982 et 2000,
85 000 enfants sont nés en France grâce à une FIV (estimation basée sur une exploitation croisée
de l’enquête FIVNAT et des données administratives). Cinq bilans mondiaux et deux bilans
européens ont été consacrés à la FIV mais leur exploitation reste limitée par les problèmes de
non-exhaustivité des données pour des régions telles que l’Europe méridionale et orientale. Les
taux de succès de la FIV sont de l’ordre de 15 % à 20 % de grossesses par ponction. Cependant,
ces taux chutent quand l’âge de la femme augmente et lorsque l’homme a un sperme présentant
des anomalies sévères. Dans le cas d’une infertilité masculine sévère, l’insémination artificielle
avec spermatozoïdes de donneur (IAD) a longtemps été la seule réponse médicale, mais elle pose
le problème de l’acceptation d’un donneur de sperme. Depuis 1992, une nouvelle technique de
FIV est proposée : l’injection intra-cytoplasmique de spermatozoïde (ICSI). Cette technique
s’est largement développée en France et dans de nombreux pays : elle représentait 30 % à 60 %
de l’activité de fécondation assistée en 1998. Malgré ce développement important, de nombreus-
es questions demeurent sur les conséquences de la technique, en particulier quant à l’état de
santé à court et long terme des enfants conçus par ICSI.
LA ROCHEBROCHARD Élise de.– Sobre los hombres que recurren a la asistencia médica para pro-
crear: IAD, FIV, ICSI, balance de una revolución en la respuesta médica a la infertili-
dad masculina
Ante los problemas de infertilidad, que afectan entre el 15% y el 20% de las parejas, se
ha producido una evolución de las técnicas de fecundación in vitro (FIV). Entre 1982 y el 2000
se produjeron 85,000 nacimientos en Francia gracias a la FIV (estimación basada en una explo-
tación combinada de la encuesta FIVNAT y de datos administrativos). Aunque se han realizado
cinco balances del FIV a nivel mundial y dos a nivel europeo, la explotación de tales balances
es limitada debido a problemas de falta de exhaustividad de los datos para ciertas regiones, por
ejemplo Europa meridional y del Este. Las tasas de éxito de la FIV son del orden del 15 al 20%
de embarazos por punción. No obstante, estas tasas disminuyen fuertemente cuando la edad de
la mujer aumenta o cuando el esperma del hombre presenta anomalías severas. En casos de in-
fertilidad masculina severa, la única respuesta médica ha sido durante mucho tiempo la insemi-
nación artificial con espermatozoides del donante (IAD), pero tal método requiere la aceptación
del donante de esperma. Desde 1992 existe una nueva técnica de FIV: la inyección intra-cito-
plásmica de espermatozoide (ICSI). Esta técnica se ha desarrollado ampliamente tanto en Fran-
cia como en otros países, hasta representar entre el 30% y el 60% de la actividad de fecundación
asistida en 1998. A pesar de una evolución tan significativa, todavía existen muchas dudas en
cuanto a las consecuencias de ésta técnica, especialmente en cuanto al estado de salud a corto y
a largo plazo de los niños concebidos a partir de ella.
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